XENE’s Azetukalner nears U.S. launch for focal onset seizures
Azetukalner is advancing toward U.S. commercialization for focal onset seizures, with robust efficacy across four doses. Launch is set to target epileptologists and expand to general neurologists under a specialty pharma model, with plans for premium pricing.